The use of clinical and biological characteristics to predict outcome following First Episode Psychosis

Australian and New Zealand Journal of Psychiatry

Volumn 49, Issue 1, 2015, Pages 24-35

  Oliver Schubert, K ^a   Clark, Scott R ^a   Baune, Bernhard T ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

first episode psychosis; functioning; predictive modeling; Schizophrenia; trajectories

Indexed keywords

BIOLOGICAL MARKER; PROTEIN;

BRAIN SIZE; DISEASE COURSE; GRAY MATTER; HUMAN; ILLNESS TRAJECTORY; NEGATIVE SYNDROME; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PROTEOMICS; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIMULATION; SUPPORT VECTOR MACHINE; BLOOD; BRAIN; COGNITIVE DEFECT; COMPLICATION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

BIOMARKERS; BRAIN; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; PSYCHOTIC DISORDERS;

EID: 84919458893     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867414560650     Document Type: Review

References (96)

1. Albert N, Bertelsen M, Thorup A, et al. Predictors of recovery from psychosis Analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5 years. Schizophrenia Research. 2011 ; 125: 257-266
2. Alvarez-Jimenez M, Gleeson JF, Henry LP, et al. Prediction of a single psychotic episode: A 7.5-year, prospective study in first-episode psychosis. Schizophrenia Research. 2011 ; 125: 236-246
3. Alvarez-Jimenez M, Gleeson JF, Henry LP, et al. Road to full recovery: Longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. Psychological Medicine. 2012 ; 42: 595-606
4. Andreasen NC, Liu D, Ziebell S, et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: A prospective longitudinal MRI study. American Journal of Psychiatry. 2013 ; 170: 609-615
5. Andreasen NC, Nopoulos P, Magnotta V, et al. Progressive brain change in schizophrenia: A prospective longitudinal study of first-episode schizophrenia. Biological Psychiatry. 2011 ; 70: 672-679
6. Ayesa-Arriola R, Perez-Iglesias R, Rodriguez-Sanchez JM, et al. Predictors of neurocognitive impairment at 3 years after a first episode non-affective psychosis. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2013 ; 43: 23-28
7. Banati R, Hickie IB. Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders. Medical Journal of Australia. 2009 ; 190: S26-32
8. Baune BT, Thome J. Translational research approach to biological and modifiable risk factors of psychosis and affective disorders. World Journal of Biological Psychiatry. 2011 ; 12: 28-34
9. Benoit A, Bodnar M, Malla AK, et al. The structural neural substrates of persistent negative symptoms in first-episode of non-affective psychosis: A voxel-based morphometry study. Frontiers in Psychiatry. 2012 ; 3: 42
10. Bertelsen M, Jeppesen P, Petersen L, et al. Course of illness in a sample of 265 patients with first-episode psychosis - five-year follow-up of the Danish OPUS trial. Schizophrenia Research. 2009 ; 107: 173-178
11. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. British Journal of Psychiatry Supplement. 1998 ; 172: 53-59
12. Bodnar M, Achim AM, Malla AK, et al. Functional magnetic resonance imaging correlates of memory encoding in relation to achieving remission in first-episode schizophrenia. British Journal of Psychiatry. 2012a ; 200: 300-307
13. Bodnar M, Harvey PO, Malla AK, et al. The parahippocampal gyrus as a neural marker of early remission in first-episode psychosis: A voxel-based morphometry study. Clinical Schizophrenia & Related Psychoses. 2011 ; 4: 217-228
14. Bodnar M, Malla AK, Joober R, et al. Neural markers of early remission in first-episode schizophrenia: A volumetric neuroimaging study of the parahippocampus. Psychiatry Research. 2012b ; 201: 40-47
15. Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: Do the cognitive deficits progress over, or after, the onset of psychosis?. Schizophrenia Bulletin. 2014 ; 40: 744-755
16. Cardenas V, Abel S, Bowie CR, et al. When functional capacity and real-world functioning converge: The role of self-efficacy. Schizophrenia Bulletin. 2013 ; 39: 908-916
17. Case M, Stauffer VL, Ascher-Svanum H, et al. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychological Medicine. 2011 ; 41: 1291-1300
18. Chuma J, Mahadun P. Predicting the development of schizophrenia in high-risk populations: Systematic review of the predictive validity of prodromal criteria. British Journal of Psychiatry. 2011 ; 199: 361-366
19. Clark S, Pradhan M, Adams R, et al HINZ 2003 (2nd: 2003: Darling Harbour, NSW). Brunswick East, Victoria: Health Informatics Society of Australia (HISA); Royal Australian College of General Practitioners (RACGP) ; 2003: 149-158.
20. Clark S, Pradhan M, Adams R, et al. Opportunities to reduce delay to antibiotic in community acquired pneumonia: Early diagnosis modelling and simulation. National Health Informatics Conference (13th: 2005: Melbourne, Victoria) ; 2005 Brunswick East, Victoria: Health Informatics Society of Australia ; 2005. 220.
21. Clark SR University of Adelaide, Department of Medicine, Health Informatics Unit. Adelaide: University of Adelaide ; 2009: 272.
22. Correll CU, Sikich L, Reeves G, et al. Metformin for antipsychotic-related weight gain and metabolic abnormalities: When, for whom, and for how long?. American Journal of Psychiatry. 2013 ; 170: 947-952
23. Crespo-Facorro B, de la Foz VO, Ayesa-Arriola R, et al. Prediction of acute clinical response following a first episode of non affective psychosis: Results of a cohort of 375 patients from the Spanish PAFIP study. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2013 ; 44: 162-167
24. Crumlish N, Whitty P, Clarke M, et al. Beyond the critical period: Longitudinal study of 8-year outcome in first-episode non-affective psychosis. British Journal of Psychiatry. 2009 ; 194: 18-24
25. de Castro-Manglano P, Mechelli A, Soutullo C, et al. Structural brain abnormalities in first-episode psychosis: Differences between affective psychoses and schizophrenia and relationship to clinical outcome. Bipolar Disorders. 2011 ; 13: 545-555
26. De Herdt A, Wampers M, Vancampfort D, et al. Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: A meta-analysis. Schizophrenia Research. 2013 ; 149: 48-55
27. Demjaha A, Murray RM, McGuire PK, et al. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. American Journal of Psychiatry. 2012 ; 169: 1203-1210
28. Emsley R, Chiliza B, Asmal L, et al. The concepts of remission and recovery in schizophrenia. Current Opinion in Psychiatry. 2011 ; 24: 114-121
29. English JA, Pennington K, Dunn MJ, et al. The neuroproteomics of schizophrenia. Biological Psychiatry. 2011 ; 69: 163-172
30. Faerden A, Barrett EA, Nesvag R, et al. Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis. Psychiatry Research. 2013 ; 210: 55-61
31. Focking M, Dicker P, English JA, et al. Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. Archives of General Psychiatry. 2011 ; 68: 477-488
32. Gaebel W, Riesbeck M, Wolwer W, et al. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophrenia Research. 2014 ; 152: 478-486
33. Gale C, Glue P, Gallagher S. Bayesian analysis of posttest predictive value of screening instruments for the psychosis high-risk state. JAMA Psychiatry. 2013 ; 70: 880-881
34. Glahn DC, Laird AR, Ellison-Wright I, et al. Meta-analysis of gray matter anomalies in schizophrenia: Application of anatomic likelihood estimation and network analysis. Biological Psychiatry. 2008 ; 64: 774-781
35. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. American Journal of Psychiatry. 1996 ; 153: 321-330
36. Green MF, Kern RS, Braff DL, et al. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the 'right stuff'?. Schizophrenia Bulletin. 2000 ; 26: 119-136
37. Guest PC, Gottschalk MG, Bahn S. Proteomics: Improving biomarker translation to modern medicine?. Genome Medicine. 2013a ; 5: 17
38. Guest PC, Martins-de-Souza D, Schwarz E, et al. Proteomic profiling in schizophrenia: enabling stratification for more effective treatment. Genome Medicine. 2013b ; 5: 25
39. Haijma SV, Van Haren N, Cahn W, et al. Brain volumes in schizophrenia: A meta-analysis in over 18 000 subjects. Schizophrenia Bulletin. 2013 ; 39: 1129-1138
40. Harding CM, Brooks GW, Ashikaga T, et al. The Vermont longitudinal study of persons with severe mental illness, II: Long-term outcome of subjects who retrospectively met DSM-III criteria for schizophrenia. American Journal of Psychiatry. 1987 ; 144: 727-735
41. Harvey PD, McClure MM, Patterson TL, et al. Impairment in functional capacity as an endophenotype candidate in severe mental illness. Schizophrenia Bulletin. 2012 ; 38: 1318-1326
42. Hatcher S. Decision analysis in psychiatry. British Journal of Psychiatry. 1995 ; 166: 184-190
43. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: A meta-analysis of the outcome literature. American Journal of Psychiatry. 1994 ; 151: 1409-1416
44. Hickie IB, Scott J, McGorry PD. Clinical staging for mental disorders: A new development in diagnostic practice in mental health. Medical Journal of Australia. 2013 ; 198: 461-462
45. Hovington CL, Bodnar M, Joober R, et al. Impairment in verbal memory observed in first episode psychosis patients with persistent negative symptoms. Schizophrenia Research. 2013 ; 147: 223-229
46. Huber G. The heterogeneous course of schizophrenia. Schizophrenia Research. 1997 ; 28: 177-185
47. Kaneda Y, Jayathilak K, Meltzer H. Determinants of work outcome in neuroleptic-resistant schizophrenia and schizoaffective disorder: Cognitive impairment and clozapine treatment. Psychiatry Research. 2010 ; 178: 57-62
48. Killackey E, Jackson HJ, McGorry PD. Vocational intervention in first-episode psychosis: Individual placement and support v. treatment as usual. British Journal of Psychiatry. 2008 ; 193: 114-120
49. Koike S, Takano Y, Iwashiro N, et al. A multimodal approach to investigate biomarkers for psychosis in a clinical setting: The integrative neuroimaging studies in schizophrenia targeting for early intervention and prevention (IN-STEP) project. Schizophrenia Research. 2013 ; 143: 116-124
50. Koutsouleris N, Borgwardt S, Meisenzahl EM, et al. Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: Results from the FePsy study. Schizophrenia Bulletin. 2012 ; 38: 1234-1246
51. Krishnan M, Temel JS, Wright AA, et al. Predicting life expectancy in patients with advanced incurable cancer: A review. Journal of Supportive Oncology. 2013 ; 11: 68-74
52. Lappin JM, Morgan C, Chalavi S, et al. Bilateral hippocampal increase following first-episode psychosis is associated with good clinical, functional and cognitive outcomes. Psychological Medicine. 2014 ; 44: 1279-1291
53. Levine SZ, Lurie I, Kohn R, et al. Trajectories of the course of schizophrenia: From progressive deterioration to amelioration over three decades. Schizophrenia Research. 2011 ; 126: 184-191
54. McGee S. Simplifying likelihood ratios. Journal of General Internal Medicine. 2002 ; 17: 646-649
55. McGorry PD, Hickie IB, Yung AR, et al. Clinical staging of psychiatric disorders: A heuristic framework for choosing earlier, safer and more effective interventions. Australia and New Zealand Journal of Psychiatry. 2006 ; 40: 616-622
56. Mamah D, Harms MP, Barch D, et al. Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness. Frontiers in Psychiatry. 2012 ; 3: 96
57. Manchanda R, Norman R, Malla A, et al. EEG abnormalities and 3-year outcome in first episode psychosis. Acta Psychiatrica Scandinavica. 2008 ; 117: 277-282
58. Medalia A, Saperstein AM. Does cognitive remediation for schizophrenia improve functional outcomes?. Current Opinion in Psychiatry. 2013 ; 26: 151-157
59. Milev P, Ho BC, Arndt S, et al. Initial magnetic resonance imaging volumetric brain measurements and outcome in schizophrenia: A prospective longitudinal study with 5-year follow-up. Biological Psychiatry. 2003 ; 54: 608-615
60. Moller HJ, Schmid-Bode W, von Zerssen D. Prediction of long-term outcome in schizophrenia by prognostic scales. Schizophrenia Bulletin. 1986 ; 12: 225-234
61. Mourao-Miranda J, Reinders AA, Rocha-Rego V, et al. Individualized prediction of illness course at the first psychotic episode: A support vector machine MRI study. Psychological Medicine. 2012 ; 42: 1037-1047
62. Orru G, Pettersson-Yeo W, Marquand AF, et al. Using Support Vector Machine to identify imaging biomarkers of neurological and psychiatric disease: A critical review. Neuroscience & Biobehavioral Reviews. 2012 ; 36: 1140-1152
63. Owens DK, Shachter RD, Nease RF. Representation and analysis of medical decision problems with influence diagrams. Medical Decision Making. 1997 ; 17: 241-262
64. Palaniyappan L, Marques TR, Taylor H, et al. Cortical folding defects as markers of poor treatment response in first-episode psychosis. JAMA Psychiatry. 2013 ; 70: 1031-1040
65. Pantelis C, Yucel M, Wood SJ, et al. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophrenia Bulletin. 2005 ; 31: 672-696
66. Peer JE, Spaulding WD. Heterogeneity in recovery of psychosocial functioning during psychiatric rehabilitation: An exploratory study using latent growth mixture modeling. Schizophrenia Research. 2007 ; 93: 186-193
67. Pelayo-Teran JM, Diaz FJ, Perez-Iglesias R, et al. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis. Psychological Medicine. 2014 ; 44: 1-14
68. Ramshaw H, Xu X, Jaehne EJ, et al. Locomotor hyperactivity in 14-3-3zeta KO mice is associated with dopamine transporter dysfunction. Translational Psychiatry. 2013 ; 3: e327
69. Rangaswamy T. Twenty-five years of schizophrenia: The Madras longitudinal study. Indian Journal of Psychiatry. 2012 ; 54: 134-137
70. Remington G, Agid O, Foussias G, et al. Clozapine's role in the treatment of first-episode schizophrenia. American Journal of Psychiatry. 2013 ; 170: 146-151
71. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry. 2004 ; 161: 473-479
72. Rund BR, Melle I, Friis S, et al. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse. Schizophrenia Research. 2007 ; 91: 132-140
73. Schaufelberger MS, Lappin JM, Duran FL, et al. Lack of progression of brain abnormalities in first-episode psychosis: A longitudinal magnetic resonance imaging study. Psychological Medicine. 2011 ; 41: 1677-1689
74. Schubert KO, Focking M, Prehn JH, et al. Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder?. Molecular Psychiatry. 2012 ; 17: 669-681
75. Schwarz E, Guest PC, Rahmoune H, et al. Identification of a biological signature for schizophrenia in serum. Molecular Psychiatry. 2012a ; 17: 494-502
76. Schwarz E, Guest PC, Steiner J, et al. Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Translational Psychiatry. 2012b ; 2: e82
77. Schwarz E, Izmailov R, Spain M, et al. Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomarker Insights. 2010 ; 5: 39-47
78. Schwarz E, van Beveren NJ, Ramsey J, et al. Identification of Subgroups of Schizophrenia Patients With Changes in Either Immune or Growth Factor and Hormonal Pathways. Schizophrenia Bulletin. 2014 ; 40: 787-795
79. Shah J, Eack SM, Montrose DM, et al. Multivariate prediction of emerging psychosis in adolescents at high risk for schizophrenia. Schizophrenia Research. 2012 ; 141: 189-196
80. Simon AE, Gradel M, Cattapan-Ludewig K, et al. Cognitive functioning in at-risk mental states for psychosis and 2-year clinical outcome. Schizophrenia Research. 2012 ; 142: 108-115
81. Simon J, Pilling S, Burbeck R, et al. Treatment options in moderate and severe depression: Decision analysis supporting a clinical guideline. British Journal of Psychiatry. 2006 ; 189: 494-501
82. Sommer IE, van Westrhenen R, Begemann MJ, et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: An update. Schizophrenia Bulletin. 2014 ; 40: 181-191
83. Sox HC, Blatt MA, Higgins MC, et al Medical Decision Making. West Sussex: John Wiley & Sons ; 2013 :
84. Steyerberg EW, Moons KG, van der Windt DA, et al. Prognosis Research Strategy (PROGRESS) 3: Prognostic model research. PLoS Med. 2013 ; 10: e1001381
85. Strauss JS, Carpenter WT. The prediction of outcome in schizophrenia. I. Characteristics of outcome. Archives of General Psychiatry. 1972 ; 27: 739-746
86. Swerdlow NR. Are we studying and treating schizophrenia correctly?. Schizophrenia Research. 2011 ; 130: 1-10
87. Thara R. Twenty-year course of schizophrenia: The Madras Longitudinal Study. Canadian Journal of Psychiatry. 2004 ; 49: 564-569
88. Thorup A, Albert N, Bertelsen M, et al. Gender differences in first-episode psychosis at 5-year follow-up - two different courses of disease? Results from the OPUS study at 5-year follow-up. European Psychiatry. 2014 ; 29: 44-51
89. Waddington JL, Lane A, Scully P, et al. Early cerebro-craniofacial dysmorphogenesis in schizophrenia: A lifetime trajectory model from neurodevelopmental basis to 'neuroprogressive' process. Journal of Psychiatric Research. 1999 ; 33: 477-489
90. Weickert CS, Weickert TW, Pillai A, Buckley PF. Biomarkers in schizophrenia: A brief conceptual consideration. Disease Markers. 2013 ; 35: 3-9
91. Werneke U, Ott M, Renberg ES, et al. A decision analysis of long-term lithium treatment and the risk of renal failure. Acta Psychiatrica Scandinavica. 2012 ; 126: 186-197
92. Wigman JT, van Winkel R, Raaijmakers QA, et al. Evidence for a persistent, environment-dependent and deteriorating subtype of subclinical psychotic experiences: A 6-year longitudinal general population study. Psychological Medicine. 2011 ; 41: 2317-2329
93. Willke RJ, Zheng Z, Subedi P, et al. From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: A primer. BMC Medical Research Methodology. 2012 ; 12: 185
94. Wolwer W, Brinkmeyer J, Stroth S, et al. Neurophysiological correlates of impaired facial affect recognition in individuals at risk for schizophrenia. Schizophrenia Bulletin. 2012 ; 38: 1021-1029
95. Wood SJ, Yung AR, Pantelis C. Cognitive precursors of severe mental disorders. Cognitive Neuropsychiatry. 2013 ; 18: 1-8
96. Yokota F, Thompson KM. Value of information literature analysis: A review of applications in health risk management. Medical Decision Making. 2004 ; 24: 287-298